Nebenwirkungen · Adcetris
ADCETRIS 50 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 19
HOS-126077 · Präparat HOS-096209
In the clinical trial (HD21 [BrECADD]) of ADCETRIS as combination therapy, treatment emergent peripheral sensory neuropathy occurred in 38.8% of the population; peripheral motor neuropathy occurred in 3.6% of patients. Peripheral sensory neuropathy as a serious adverse event did not lead to discontinuation in any patients, led to dose reduction in 4.7% and treatment delay in 1.5% of patients. Peripheral motor neuropathy as a serious adverse event did not lead to discontinuation in any patients, led to dose reduction in 0.7%, and treatment delay in 0.1% of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-20T10:51:00Z · SHA-256 a80608da289c54a95c6f3ae56a63c85084ccf90e8e43e395dd22479d252877cb · Passage 4fa3c6f801518039531e7a3297b7db31a15a2bbdac9e2b5794f21241c30a7d0d · Zeichen 16705–17276 im Abschnitt